Ratioing the resected gastric volume to the number of fired staplers predicts weight loss
Ratioing the resected gastric volume (RGV) to the number of staplers fired (SF) could be used to predict midterm weight loss, according...
top of page
Headlines
Ratioing the resected gastric volume to the number of fired staplers predicts weight loss
Ratioing the resected gastric volume (RGV) to the number of staplers fired (SF) could be used to predict midterm weight loss, according...
Research
Ratioing the resected gastric volume to the number of fired staplers predicts weight loss
Ratioing the resected gastric volume (RGV) to the number of staplers fired (SF) could be used to predict midterm weight loss, according...
Arrowhead initiates phase 1/2a study of ARO-INHBE for obesity
Arrowhead Pharmaceuticals has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA...
Survey finds 93.4% of bariatric patients vs 51.4% of GLP-1 patients have the same treatment again
Over 93% of bariatric patients said they would undergo bariatric surgery again, compared with just over half of those who said they would...
Wave Life Sciences announces submission of first clinical trial application for WVE-007 in obesity
Wave Life Sciences has submitted its first clinical trial application (CTA) for WVE-007 in obesity. WVE-007 is an investigational...
Rhythm gains expanded indication for IMCIVREE (setmelanotide) for patients as young as 2 years old
Rhythm Pharmaceuticals has received an expanded indication for IMCIVREE (setmelanotide) to include children as young as 2 years old to...
REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight
Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
Preoperative antihypertensive drugs and visceral fat area can predict hypertension remission and recurrence post-LSG
By combining the number of preoperative antihypertensive drugs (ADs) and visceral fat area (VFA) may help predict hypertension (HTN)...
Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss
Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...
Racial and ethnic groups face barriers to obtaining OMMs
Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications (OMMs) to...
Survey finds 50% of post-bariatric surgery patients feel less stress during the holidays
About 50% of bariatric patients reported experiencing significantly less or less stress during the holidays compared to the holiday...
Journal Watch 18/12/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Industry
All caught up?
New: Directory
Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.
Events
Tweets
bottom of page